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Abstract
Background:  It is postulated that the unusual manifestations of Kaposis's sarcoma cells in
nonendothelial brain tissues and on eyeballs in advanced acquired immune deficiency syndrome
(AIDS) cases are metastasized AIDS-Kaposi's sarcoma cells arising from vascular endothelial cells.
Methods:  Experiments were performed to explore the above hypothesis by testing for
intercellular adhesion molecule-1 (CD54 antigens) on cutaneous AIDS-Kaposi's sarcoma cells as
well as on AIDS-Kaposi's sarcoma cells isolated from eyeballs as studies have illustrated that, unlike
localized Kaposi's sarcoma cells of primary lesions, proliferating Kaposi's sarcoma cells in proximity
to primary lesions express a negative or diminished phenotype when evaluated for identical surface
antigens. Parallel CD54 antigen tests were done on vascular endothelial cells and monocytes/
macrophages as endothelial cells are considered evolutionarily related to Kaposi's sarcoma cells
and monocytes/macrophages are ideal CD54 antigen positive controls.
Results: Our data showed that only AIDS-Kaposi's sarcoma cells of the eyes did not express
CD54 antigens.
Conclusions: We therefore report that our findings support the postulation suggesting AIDS-
Kaposi's sarcoma dissemination in advanced AIDS patients in keeping with their vascular
endothelial heredity.
Introduction
Recent evidence documenting the preponderance of en-
dothelial cells (ECs) in and about Kaposi's sarcoma (KS)
lesions is just one factor that is indicative of primary KS
formation from EC defects [1,2]. Consistent with this
knowledge is the postulation that the occasional appear-
ances of Kaposi's sarcoma cells (KSCs) in nonendothelial
cerebral tissues and on eyeballs in advanced acquired im-
mune deficiency syndrome (AIDS) patients are secondary
AIDS-KS aggregates, that owe their existence to migrated
AIDS-KSCs [1–3]. This observation is further refined to
the understanding that these seldom and, if any, dissemi-
nating AIDS-KSCs are small in population as compared to
the majority of AIDS-KSCs, which remain localized, but
also that there is the need to characterize the difference be-
tween these two populations of AIDS-KSCs in order to an-
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alytically show that dissemination, possibly, has taken
place [4].
According to an extensive histological determination, a di-
rect correlation exists between surface ligand (Ag) expres-
sion and proliferation among KSCs [5]. The same analysis
also documents a similar correlation between Ag expres-
sion and metastasis for an endothelial tumor [5]. These
findings suggest that because of correlations and ancestral
connections, Ag integrity on AIDS-KSCs is crucial in estab-
lishing merit of the metastasis theory particularly as Ag
sensitivity is frequently utilized in histopathology not
only to diagnose tumor dissemination but also to predict
benign to cancerous transformation [5].
Now, when peripheral blood lymphocytes (PBLs) are al-
losensitized with recombinant interleukin-2 (rIL-2) they
develop into cytotoxic lymphokine-activated killer (LAK)
cells [6]. These LAK-cells (effectors) are capable of lysing a
wide variety of tumors (targets) both in vitro and in vivo
through Ag mediated interactions [6,7]. In addition, the
Ag mediated interactions of LAK effectors also target and
cause cytotoxicity to vascular ECs and monocytes/macro-
phages (MΦ ) [8,9]. It was therefore proposed that the
presence of heterogeneous LAK-cell Ags on vascular ECs,
MΦ  and tumor cells would make it possible to obviate of
the complicating injury to ECs and MΦ  in LAK-cell immu-
notherapy via the application of monoclonal antibodies
(mAbs) to selectively inhibit EC and MΦ  damage [10].
Pursuant to this approach, we incorporated the cold-target
inhibition technique [11] in chromium release assays to
detect possible heterogeneity of LAK-cell Ags on AIDS-
KSCs, vascular ECs and MΦ [10]. Data accumulated then
showed that unlike cutaneous AIDS-KS10 cells, AIDS-
KS21 cells collected from ocular lesions did not cold-tar-
get inhibit EC lysis [10]. This suggested differences in LAK-
cell Ags of AIDS-KS21 cells versus AIDS-KS10 cells and
ECs, specifically, pointing to intercellular adhesion mole-
cule-1 (ICAM-1) or CD54 Ags as studies have repeatedly
elucidated ICAM-1 on targets binding to lymphocyte
function associated antigen-1 (LFA-1) on LAK effectors in
LAK-cell attacks [12]. In this project we explore the metas-
tasis postulation by testing for CD54 Ag presentations on
vascular ECs, MΦ  and AIDS-KS21/-KS10 cells. We report
that our combined data support the postulation suggest-
ing AIDS-KS or epidemic-KS dissemination within the
confines of their vascular endothelial heredity.
Results and Discussion
LAK-cell cytotoxicities to tumor cells, virally or microbial-
ly infected cells, vascular ECs and MΦ  occur via the adhe-
sion of effectors to targets facilitated by LFA-1 Ags on
effectors interacting with ICAM-1 or CD54 moieties (Ags)
on targets [12]. RH1-38 is a murine mAb, which inhibits
LAK-cell cytotoxicity by binding to the homologous β
chains or CD18 Ags of LFA-1 [13]. In our present study we
treated LAK effectors with RH1-38 in chromium release
cytotoxicity assays to test for the presence of CD54 Ags on
MΦ , vascular ECs and on both AIDS-KS21 and AIDS-KS10
cells. Our results herein showed that although RH1-38 did
not inhibit killing of AIDS-KS21 cells, it concomitantly in-
hibited rupture of AIDS-KS10 cells, vascular ECs and MΦ
(Table 1). Combining this finding with our previous data,
where AIDS-KS21 cells failed to cold-target inhibit lysis of
vascular ECs, as otherwise demonstrated by AIDS-KS10
cells [10], summarize that AIDS-KS21 cells bore either di-
minished or negative CD54 Ag composition. Published
papers to date have reported CD54 Ags on several other
AIDS-KS cell lines unaffected following multiple passages
in vitro [14], and that no significant immunophenotyping
differences exist between AIDS-KS3, -KS6 and -KS8 cells at
comparable stages [15].
In our earlier paper, we specified that AIDS-KS21 cells
originated from an eye lesion, whereas, AIDS-KS10, -KS8
and -KS3 cells were cutaneous, visceral and pleural fluid
isolates, respectively [10]. Juxtaposed was put the observa-
tion that the differences in reactions of AIDS-KS21 cells
may be related to location, however, a plausible explana-
tion could not be proposed [10]. In light of recent evi-
dence, we suspect the following histopathogenesis.
Kaposi's sarcoma (KS) are widely accepted as EC deriva-
tives of either vascular or lymphatic lineage, but the pre-
cise EC progenitor remains unestablished [12,16,17].
Nevertheless, evidence illustrating histological similarities
between KSCs and ECs, coupled with EC Ag detections on
KSCs, lend credence to this evolution [1,2,16,17]. KS, by
itself, does not behave like other soft tissue sarcomas,
which can proceed to metastasize after growing locally; it
is a stationary tumor, which arises in numerous sites via
multicentric development [1,2,4,16,17]. However, AIDS-
KS or epidemic-KS presents an aggressive form capable of
drastic histopathogenesis [1,2,4,16,17]. One manifesta-
tion of such aggressiveness is that on rare instances AIDS-
KS can involve brain and, or, eyes in advanced AIDS pa-
tients [1,2]. It is widely held that since eyes and brain are
devoid of lymphatic endothelium, these organs are un-
likely sources of primary KS if KSCs are indeed derived
from lymphatic endothelium [1,2]. Aside from this in-
sight, research has shown AIDS-KS capable of angiogen-
esis, metastasis and tumorigenicity in mice [18,19].
Owing to such detail, the occurrences of AIDS-KS in brain
and on eyes in propinquity to cranial nerves, minute cap-
illaries and associated blood vessels are attributed to vas-
cular endothelial alteration [1–3]. And in keeping with
this evolutionary profile, occurrences of AIDS-KS in non-
endothelial, nonvascularized cerebral sites and on con-
junctiva are postulated to be products of AIDS-KS
metastasis [1–3]. One investigation reported that al-Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/11
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though AIDS-KS skin biopsies expressed the cell surface
proenzyme, procathepsin L, neighboring AIDS-KSCs,
which were characterized predominantly by vascular en-
dothelial cell proliferation, as in an angiomatous lesion,
did not express the protease, eventhough, adjoining
blood vessels stained positively [20]. Another examina-
tion found diminished or negative reactions for UEA-1
lectin, HLA-DR and OKM5 Ags on KSCs, which were in
adjacent proliferating areas slightly distant from their EC-
mix surrounding capillaries [5]. In addition, cells of the
vascular endothelial tumor, malignant angioendothelio-
ma, which bore the blood group H Ag in premetastatic
stage had somehow lost the Ag when metastasis occurred
[5]. Further probing revealed lymphatic tumors not to dis-
play this differentiating property [5]. Therefore, this inva-
sive phenomenon possibly explains the paucity of CD54
Ags on AIDS-KS21 cells that rendered them unprotected
following mAb treatment. Such a course would be consist-
ent with the view that the failure of KSCs to exhibit uni-
form staining for Ags suggests differences in their
proliferation stages particularly as mutated cells are un-
derstood to be capable of altering their surface Ag expres-
sion [2,17].
Conclusions
In conclusion, the situation of AIDS-KSCs on eyeballs is
possibly a consequence of rare epidemic-KS dissemina-
tion in keeping with their vascular endothelial evolution.
The relevance of our findings could help to better under-
stand the nature of AIDS-KSCs and KSCs.
Materials and Methods
PBLs
PBLs were obtained via leukapheresis from 2 patients pre-
paring for bone marrow transplantation at Norris Cancer
Hospital, USC School of Medicine, Los Angeles, CA, USA.
Mononuclear cells (MNCs) were separated by centrifuga-
tion over Ficoll-hypaque (1.077 g/ml) (Organon Teknika
Corporation, Durham, NC, USA). The banded cells were
collected, washed twice with calcium (Ca2+)- and magne-
sium (Mg2+)-free Hank's balanced salt solution (HBSS)
(Gibco, Grand Island, NY, USA), and cryopreserved with
10% dimethyl sulfoxide (Tera Pharmaceuticals Incorpo-
rated, Buena Park, CA, USA) in pentastarch (hydroxyethyl
starch) serum albumin (Dupont, Wilmington, DE, USA)
at concentrations of 20–50 million cells/ml and kept in
liquid nitrogen. At the time of activation, frozen MNCs
were thawed quickly in a 37°C water bath and suspended
in complete medium (CM) comprising of RPMI1640
(Gibco) with 0.1 mM nonessential amino acids and sodi-
um pyruvate (Microbiological Associate, Walkersville,
MD, USA), 5 ×  10-5 M 2-mercaptoethanol (Sigma, Saint
Louis, MO, USA), 5% heat inactivated fetal calf serum
(FCS) (Flow Laboratories, McLean, VA, USA), 1% L-
glutamine (Irvine Scientific, Santa Ana, CA, USA), and
100 U/ml penicillin with 100 µg/ml streptomycin (Irvine
Scientific). The cells were then washed twice, counted and
diluted to 1 million cells/ml all using CM.
Table 1: Results of 51Cr release assays of labeled (H) vascular ECs, MΦ , AIDS-KS10 and AIDS-KS21 cells all at 50:1 E:H ratio and with: 
NMS-1 at 1:400 and 1:100 dilutions (columns 2 & 3), mAb RH1-38 also at 1:400 and 1:100 dilutions (columns 4 & 5), neither RH1-38 nor 
NMS-1 (column 6). Values in brackets indicate percentage (%) inhibition of NMS-1 (1:400) lysis.
E:Ab NMS-1 (1:400) NMS-1 (1:100) RH1-38 (1:400) RH1-38 (1:400) NoRH1-38/NMS-1
Cell Type (H) Experiment # 1 Percent (%) Lysis ± SEM
I. MΦ 60 ± 4.1 50 ± 4.9 19 ± 0.9(68) 1 ± 0.8(98) 60 ± 3.9
II. Vascular ECs 67 ± 2.8 68 ± 2.7 30 ± 0.6(55) 5 ± 0.3(93) 66 ± 1.3
III. AIDS-KS10 85 ± 0.3 75 ± 1.3 33 ± 0.7(61) 8 ± 0.6(91) 80 ± 2.4
IV. AIDS-KS21 81 ± 4.3 80 ± 2.2 75 ± 2.0 (7) 74 ± 4.5(9) 81 ± 4.9
Experiment # 2 Percent (%) Lysis ± SEM
I. MΦ 40 ± 1.7 39 ± 2.8 12 ± 1.4(70) 4 ± 1.0(90) 44 ± 1.0
II. Vascular ECs 80 ± 1.2 75 ± 1.5 38 ± 0.9(53) 10 ± 0.9(88) 77 ± 0.3
III. AIDS-KS10 76 ± 2.0 74 ± 1.2 30 ± 0.3(60) 9 ± 0.6(88) 75 ± 2.0
IV. AIDS-KS21 55 ± 1.2 54 ± 1.3 49 ± 0.9(11) 54 ± 2.3 (2) 52 ± 2.1Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/11
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rIL-2 activation
In accordance with described protocols, 1 million MNCs/
ml were treated with 1000 units of rIL-2 (kindly donated
by Cetus, Emeryville, CA, USA) and immediately incubat-
ed under 5% CO2/37°C for 4 days to generate LAK-cells
[6]. These LAK-cells were then harvested, washed, count-
ed, and their concentrations adjusted to 2.5 million cells/
ml all using CM in preparation for chromium (51Cr) re-
lease assays; LAK-cells were our effectors (E).
Target cells
Vascular ECs, MΦ  and AIDS-KS10/-KS21 cells were used
as 51Cr labeled targets (H). KSCs were kindly donated by
Zaki Salahuddin and Suji Nakamura, USC School of Med-
icine; the cells were developed at USC from KS lesions of
AIDS patients at Los Angeles County General Hospital,
CA, USA. All KSCs were cultured in 75 or 150 ml gelati-
nized, sterile culture flasks (Corning Glassware, Corning,
NY, USA) containing 15–30 mls of KS medium (KSM).
KSM comprised of RPMI1640 supplemented with 15%
FCS, 4% 0.22 µm filtered nutridoma (Boehringer Man-
nheim, Indianapolis, IN, USA), and 20% activated CD4+
T-cell conditioned medium (T-cell CM) [21] (also kindly
provided by Zaki Salahuddin and Suji Nakamura). Every
2–3 days, KSCs were renewed with 15–30 mls of fresh
KSM. ECs harvested from human umbilical vein were sim-
ilarly cultured in EC medium (ECM) comprising of CM
supplemented with 4 mls of nutridoma and 30–45 µg/ml
of endothelial cell growth supplement (Collaborative Re-
search Incorporated, Bedford, MA, USA). As with KSCs,
every 2–3 days, ECs received 6 mls of fresh ECM. When
KSCs/ECs were confluent, they were trypsinized using 2 ×
trypsin-EDTA (Irvine Scientific) in Ca2+ and Mg2+-free
phosphate buffered saline (PBS), washed in CM, subcul-
tured or cryopreserved. MΦ  were isolated by culturing 2
million MNCs with 20 mls CM in 75 ml culture flasks for
2 hours under 5% CO2/37°C. Following incubation, MΦ
were separated by discarding nonadherant cells and har-
vesting adherent MΦ  by means of a cell scraper (Baxter,
McGaw Park, IL, USA), washed and counted all in CM.
mAb
mAb RH1-38 against LFA-1 was kindly supplied by Robert
Hall [13], Guthrie Research Institute, Sayre, PA, USA. The
Ab was added in dilutions of 1:100 and 1:400 per 100 µl
using HBSS. Normal mouse serum (NMS-1) was em-
ployed as a control at identical dilutions.
51Cr labeling
Concentrations of ECs, MΦ , AIDS-KS10/-KS21 were ad-
justed to 1–2 million cells/ml in CM and labeled using
500 µCi of Na51CrO4 (NEN Research Products, Boston,
MA,USA) for 2 hours under 5% CO2/37°C. After incuba-
tion, they were washed thrice, counted, and their numbers
adjusted to 1 million cells/ml all using CM.
51Cr release inhibition assay
The procedure for 51Cr release assay was modified due to
mAb additions as previously shown [10,11]. Briefly, to
96-well flat-bottom plates (Corning Glassware) were dis-
pensed 0.25 million LAK-cells/well/100 µl. Identical
number of these wells then received 100 µl of one of the
following reagents: RH1-38 at 1:100 (E:Ab), RH-138 at
1:400 (E:Ab), NMS-1 at 1:100 (E:Ab), and NMS-1 at 1:400
(E:Ab). Plates were then left at 4°C for 30 minutes to per-
mit Ab to E binding. Subsequently, single types of H were
pipetted at 50:1 E:H ratio into equal number of E with Ab
containing wells at every four predesigned E:Ab ratio.
Maximum E strength was measured by incubation of E
and H alone at 50:1 ratio; maximum isotope release was
measured by incubation of H with 0.1 N HCl alone; and
spontaneous release was measured by incubation of H
with CM alone. Plates were then exposed to 5% CO2/
37°C for 4 hours. The culture supernatants were harvested
using the Skatron Titertek System (Skatron A.S. Libergyn,
Norway) and counted in a gamma counter (Packard Auto-
Gamma-500; United Technologies Packard, Laguna Hills,
CA, USA). The percentage (%) specific lysis was calculated
by the formula:
All determinations were made in at least triplicate and
data calculated as mean ± standard error of mean (SEM).
Experiments were repeated at least once.
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